title: Gabapentin for neuropathic pain following spinal cord injury.
abstract: METHODS
  Retrospective review of patient data.
  
  
  OBJECTIVE
  To present two years of experience in the use of gabapentin for the alleviation of neuropathic pain in spinal cord injury patients.
  
  
  METHODS
  Supra-regional Spinal Cord Service, Melbourne, Australia.
  
  
  METHODS
  Data were retrieved from the medical records of all spinal cord injury patients prescribed gabapentin for neuropathic pain. Pain was assessed prior to and during treatment at 1, 3 and 6 months with a 10 cm visual analogue scale which ranged from 0 ('no pain') to 10 ('worst pain imaginable'), or by the documentation of a verbal description of pain.
  
  
  RESULTS
  Seventy-six per cent of patients receiving gabapentin reported a reduction in neuropathic pain. In those patients with data at all four measurement points, the mean pretreatment score was 8.86. Following treatment with gabapentin the score dropped to 5.23, 4.59 and 4.13 at 1, 3 and 6 months, respectively. Where only a verbal description of pain was documented, the trend was that the pretreatment report of 'unbearable' was replaced by 'liveable' during treatment.
  
  
  CONCLUSIONS
  Our experience suggests that gabapentin offers an effective therapeutic alternative for the alleviation of neuropathic pain following spinal cord injury. Controlled clinical trials are now required to confirm these observations.
authors.affiliation: Pharmacy Department, Austin & Repatriation Medical Centre, Victoria, Australia. phung@armc.org.au
authors.forename: T-P
authors.initials: TP
authors.lastname: To
authors.forename: T C
authors.initials: TC
authors.lastname: Lim
authors.forename: S T
authors.initials: ST
authors.lastname: Hill
authors.forename: A G
authors.initials: AG
authors.lastname: Frauman
authors.forename: N
authors.initials: N
authors.lastname: Cooper
authors.forename: S W
authors.initials: SW
authors.lastname: Kirsa
authors.forename: D J
authors.initials: DJ
authors.lastname: Brown
mesh_terms: D000085:Acetates / Q000627:therapeutic use*; D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000588:Amines; D002908:Chronic Disease; D003509:Cyclohexanecarboxylic Acids; D005260:Female; D000077206:Gabapentin; D006801:Humans; D008297:Male; D008875:Middle Aged; D010146:Pain / Q000188:drug therapy* / Q000209:etiology*; D010147:Pain Measurement / Q000379:methods*; D010264:Paraplegia / Q000150:complications; D011782:Quadriplegia / Q000150:complications; D015203:Reproducibility of Results; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D013119:Spinal Cord Injuries / Q000150:complications*; D028761:Withholding Treatment; D005680:gamma-Aminobutyric Acid
chemical_list: D000085:Acetates; D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin